STAT+: Will Gilead’s early data for its CAR-T therapy give it an edge over Bristol Myers?
Gilead Sciences (GILD) released top-line trial data for its Yescarta treatment that may allow the company to leapfrog over a rival in the marketing battle over CAR-T therapies.
The preliminary results of a randomized Phase 3 trial showed the treatment — which involves extracting white blood cells and genetically modifying them to attack cancer — prevented the return of large B-cell lymphoma better than the standard of care, which includes chemotherapy and a stem cell transplant. The study, called ZUMA-7, specifically examined patients whose initial treatment had failed and who were given Yescarta as a second-line treatment.
